They process and deliver antigens to T and B lymphocytes that reside in the draining lymph nodes to induce immune tolerance [20]. systematic reviews and meta-analyses, as well as to Vigabatrin summarize the most recent strategies for overcoming immunogenicity and approaches for controlling treatment failure in IBD. Keywords:inflammatory bowel disease, biologic therapy, antibodies to biologics, anti-TNF antibodies, TNF antagonist, anti-TNFa, infliximab, treatment response failure, immunogenicity, loss of performance, security == 1. IntroductionChallenges Related to the Use of Biologic Therapy in IBD Individuals == Biologic therapy for treating inflammatory bowel PRKCG disease (IBD) individuals started Vigabatrin optimistically 25 years ago [1]. Since then, approvals for medical use for IBD have been authorized for five anti-TNF medicines (infliximab, adalimumab, golimumab, certolizumab pegol), along with biosimilars [2], and for anti-IL-12/IL-23 (ustekinumab), anti-47-integrin (vedolizumab), and for some countries, for anti-4-integrins (natalizumab), etc., while additional treatments have been implemented for additional autoimmune disorders and discussed as having potential effectiveness for IBDetanercept, anti-IL-17 (secukinumab, ixekizumab, brodalumab), etc. Additionally, more recently developed small molecules for the treatment of IBD and additional inflammatory diseases have been launched (i.e., JAK inhibitors (tofacitinib)) [3], although they are not labeled as biologics. However, along with their undeniable performance in enabling IBD patients to accomplish and maintain disease remission, biological therapies face some challenges concerning safety, loss of performance, high price, etc. The 1st and most significant challenge when using biologics as monotherapy in IBD management is that only a maximum of 40% of individuals achieve a state of remission at the end of the 1st 12 months of therapy [4]. Furthermore, individuals with poor response to therapy or refractory IBD, including having extraintestinal complications, are often offered dual biologic therapy [3]. Recent systematic evaluations and meta-analyses showed that the most common adverse effects of biologics used as monotherapy in IBD are arthralgia, flares, and skin lesions (i.e., eczema, psoriasis), and the most severeinfections (odds percentage, OR 0.893.60 in different meta-analyses, OR 1.90 for opportunistic infections) and malignancies (with OR for older people (OR = 3.07)higher than for younger biologic users) [5,6,7]. Additional issues related to the optimal sequence biological therapy for IBD are still challenging. Many studies for ulcerative colitis (UC), such as GEMINI 1, VARSITY, ULTRA 2, and True North, showed lower medical remission rates with adalimumab, vedolizumab, and ozanimod after anti-TNF therapy, while additional studies, such as OCTAVE 1, 2, U-ACHIEVE/U-ACCOMPLISH, and UNIFI (ustekinumab, tofacitinib, and upadacitinib) did not. At the same time, the EXTEND and GEMINI Vigabatrin 1, 2 projects in Vigabatrin Crohns disease (CD) patients showed that adalimumab and vedolizumab are associated with prolonged lower endoscopic remission after anti-TNF therapy, but ustekinumab and risankizumab (from IM-UNIFI, FORTIFY and SEAVUE) do not result in remission. On the other hand, EVOLVE shown that vedolizumab could be used like a first-line biologic because it does not effect further anti-TNF therapy [8]. Consequently, the controversial results regarding the optimal sequence of biologics for IBD emphasize the need to explore this problem more. Another issue related to IBD treatment is the development of fresh providers. Zurba et al. explored the pipeline of novel treatments for IBD. The authors also discussed the major issues associated with biologics for IBD, namely, primary non-response, secondary loss of response, and adverse effects (short- and long-term) [9]. However, there are novel treatment approaches, such as modulation of host-microbiome relationships, stem cell therapy, fibrosis management, gut-brain axis modulation, and targeted B cell therapy. Still, a definitive therapy or long-term remission for IBD is likely not realistic at this stage of the technology [10]. Nonetheless, improvements in the medical care of IBD have risen in recent years, boosted from the innovative small molecule and novel biologic medicines discussed here. Although the observed clinical response remains sub-optimal, treatment options for IBD individuals are fast growing to help address the disease burden, morbidity, mortality, and quality of life. In the absence of large-scale tests, physician encounter has now led to prospective innovative restorative mixtures, with most data explained in case reports and case series [11]. Despite these advance, the place and future of biologics remain demanding to determine. They and additional advanced therapies (i.e., novel small Vigabatrin molecules) have made considerable contributions in providing customized treatment for IBD individuals [12]. The problems related to choosing the optimal single-agent, sequential therapy following treatment failure, dual biologic therapy, and small molecules were recently.